Bio-Rad Laboratories, Inc. to Post Q4 2024 Earnings of $2.77 Per Share, Zacks Research Forecasts (NYSE:BIO)

Bio-Rad Laboratories, Inc. (NYSE:BIO) – Equities researchers at Zacks Research reduced their Q4 2024 earnings per share estimates for shares of Bio-Rad Laboratories in a research note issued on Monday, October 14th. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings of $2.77 per share for the quarter, down from their previous forecast of $2.78. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $9.45 per share. Zacks Research also issued estimates for Bio-Rad Laboratories’ Q2 2025 earnings at $2.86 EPS, Q3 2025 earnings at $2.97 EPS and Q3 2026 earnings at $2.94 EPS.

Several other research firms have also issued reports on BIO. StockNews.com lowered shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Citigroup raised Bio-Rad Laboratories from a “neutral” rating to a “buy” rating and upped their target price for the stock from $350.00 to $400.00 in a research report on Tuesday, October 1st. Wells Fargo & Company assumed coverage on shares of Bio-Rad Laboratories in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $340.00 target price for the company. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $401.00 price objective on shares of Bio-Rad Laboratories in a research note on Friday, August 16th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, Bio-Rad Laboratories currently has a consensus rating of “Moderate Buy” and a consensus target price of $368.20.

Bio-Rad Laboratories Price Performance

NYSE BIO opened at $342.16 on Tuesday. The company has a quick ratio of 4.63, a current ratio of 6.28 and a debt-to-equity ratio of 0.18. The stock has a market capitalization of $9.76 billion, a PE ratio of -33.03 and a beta of 0.95. Bio-Rad Laboratories has a 12-month low of $261.59 and a 12-month high of $364.24. The company has a 50 day moving average price of $329.41 and a two-hundred day moving average price of $306.82.

Bio-Rad Laboratories (NYSE:BIO) last issued its earnings results on Thursday, August 1st. The medical research company reported $3.11 earnings per share for the quarter, topping the consensus estimate of $2.12 by $0.99. The company had revenue of $638.50 million for the quarter, compared to analyst estimates of $645.79 million. Bio-Rad Laboratories had a positive return on equity of 3.77% and a negative net margin of 51.73%. The business’s revenue was down 6.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.00 EPS.

Insider Activity

In related news, COO Andrew J. Last sold 3,000 shares of the business’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $329.94, for a total transaction of $989,820.00. Following the transaction, the chief operating officer now directly owns 7,559 shares in the company, valued at $2,494,016.46. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, COO Andrew J. Last sold 3,000 shares of the firm’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $329.94, for a total value of $989,820.00. Following the completion of the transaction, the chief operating officer now directly owns 7,559 shares of the company’s stock, valued at $2,494,016.46. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP James Barry sold 623 shares of the business’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $330.49, for a total transaction of $205,895.27. Following the completion of the sale, the executive vice president now directly owns 147 shares in the company, valued at $48,582.03. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 17.06% of the stock is owned by company insiders.

Hedge Funds Weigh In On Bio-Rad Laboratories

A number of hedge funds have recently modified their holdings of the stock. Van ECK Associates Corp bought a new stake in Bio-Rad Laboratories in the second quarter valued at $180,040,000. First Eagle Investment Management LLC boosted its stake in shares of Bio-Rad Laboratories by 32,296.9% in the 2nd quarter. First Eagle Investment Management LLC now owns 636,275 shares of the medical research company’s stock valued at $173,773,000 after purchasing an additional 634,311 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Bio-Rad Laboratories by 64.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 494,604 shares of the medical research company’s stock worth $135,081,000 after purchasing an additional 193,700 shares during the last quarter. Select Equity Group L.P. increased its position in shares of Bio-Rad Laboratories by 26.2% during the 2nd quarter. Select Equity Group L.P. now owns 649,522 shares of the medical research company’s stock worth $177,391,000 after purchasing an additional 134,856 shares in the last quarter. Finally, Earnest Partners LLC lifted its holdings in Bio-Rad Laboratories by 30.8% during the 1st quarter. Earnest Partners LLC now owns 514,906 shares of the medical research company’s stock valued at $178,091,000 after purchasing an additional 121,272 shares during the last quarter. 65.24% of the stock is owned by institutional investors and hedge funds.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.